Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
Aim: To investigate the factors associated with treatment selection and overall survival for
first-line EGFR-tyrosine kinase inhibitors (EGFR-TKIs) therapy among patients with non …
first-line EGFR-tyrosine kinase inhibitors (EGFR-TKIs) therapy among patients with non …
[HTML][HTML] Retrospective Evaluation of Drug-Drug Interactions With Erlotinib and Gefitinib Use in the Military Health System
TLT Luong, CN Powers, BJ Reinhardt… - Federal …, 2023 - ncbi.nlm.nih.gov
Background Erlotinib and gefitinib are epidermal growth factor receptor–tyrosine kinase
inhibitors approved for non–small cell lung cancer treatment by the US Food and Drug …
inhibitors approved for non–small cell lung cancer treatment by the US Food and Drug …
Treatment patterns and healthcare resource utilization and payments in patients with lung cancer in the Texas Medicaid program
X Ma - 2023 - repositories.lib.utexas.edu
The economic burden associated with the treatment of lung cancer is substantial. With the
introduction of targeted therapy and immunotherapy, treatment options for lung cancer …
introduction of targeted therapy and immunotherapy, treatment options for lung cancer …